President Donald Trump has, across two administrations, sought to lower drug prices for Americans, most recently with executive order “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients.” Margherita Colangelo explains why his order is unlikely to accomplish its goal.

In new research, Benjamin Wood, Sven Gallasch, Nicholas Shaxson, Katherine Sievert, and Gary Sacks write that competition underenforcement and a narrow regulatory focus on prices and output has allowed industries that produce harmful consumer products, such as tobacco or ultra-processed foods, to increase demand and, consequentially, harm to society. They argue that competition law must evolve to consider health impacts.

Anthony T. LoSasso, Ge Bai, and Lawton Robert Burns argue that critics of private equity’s involvement in healthcare ignore that it is often the only financial lifeline available to distressed healthcare providers and can introduce an improvement in outcomes, including quality of care.

Theodosia Stavroulaki reviews how the involvement of private equity in American healthcare leads to, among other negative outcomes, burnout and stress among healthcare workers, particularly physicians. She writes that the consequences could cripple America’s healthcare system.

Laura Phillips-Sawyer writes that history shows that antitrust and industrial policy have often served as complements to one another. Industrial policy has succeeded when it has targeted specific industries to invest in their ability to compete, rather than protect them from competition.

Europe is acutely aware it has fallen behind competitively, but it is struggling to find a way to recover lost ground. Cristina Caffarra writes that Europe did not find any inspiration in the American anti-monopoly movement, which underpinned the whole-of-government approach of the Biden administration. It is also faltering in developing a response to the vigorous array of tools deployed by the Trump administration to assert power at home and on the world stage. It does not need to be this way, as Europe has tremendous assets and capabilities. But it needs investment and leadership, boldness and experimentation in vision and policy design. Policymakers are beginning to see the urgency, but there is still too much narrow defensive posture by regulators sticking to their patch.

Eleanor M. Fox and Harry First warn that global strategies and political pressures are undercutting the neutral, rule-of-law competition system.

Xavier Vives argues that to create firms that can compete on the international level, the European Union does not need to ease its merger regime or encourage market power. Rather, encouraging European market integration will allow firms to draw in investment and scale up their operations.